Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets...
healthy pullback with a run up to the .5 area
followed by a pullback for a double bottom.
bullish volume confirmed, long positon and call option position open.
nice run to $5 area.
CHRS: Junshi Biosciences
2021-12-13 07:00:00
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
CHRS: Coherus BioSciences, Inc.
2021-11-15 08:30:00
Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
COHERUS BIOSCIENCES Inc., NASDAQ:CHRS , is a bioscience company that has not yet not benefited from the sector's outperformance despite significantly improving financials and the business becoming profitable. When the stock price cracks the $21 level it will unlock a significant bullish potential.
This is a signal that CHRS's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. Tickeron A.I.dvisor identified 63 similar cases where CHRS's stochastic oscillator exited the overbought zone, and 58 of them led to successful outcomes. Odds of Success: 90%. Current price $18.48 crossed the resistance line at...
My initial thoughts on $CHRS were bullish,, but the 28% short on this low floater has dampened my bullish zeal. With a $10 range from peak to trough of this pattern, it could go big either way. Green trendline = long. Red trendline= short. Do your own due diligence!!!
This is a signal that CHRS's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. Tickeron A.I.dvisor identified 61 similar cases where CHRS's stochastic oscillator exited the overbought zone, and 52 of them led to successful outcomes. Odds of Success: 85%.
Current price $17.86 crossed the resistance line at...
CHRS: Coherus BioSciences, Inc.
2018-11-30 09:30:00
Coherus BioSciences Announces Apexus Contract Agreement for 340B Hospitals and Clinics, and Q-Code Issuance from CMS
